RxDoctor Payments Data

Bao-Tran Walton

Optometrist · Tulsa, OKNPI 1295188530

Payments from drug & device makers

$1,988in general payments, 2019–2025

Across 76 payments — averaging $26.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$667
  • Bausch & Lomb Americas Inc.$481
  • AbbVie$331
  • Tarsus Pharmaceuticals, Inc.$148
  • Aerie Pharmaceuticals, Inc.$71
  • Novartis$62
  • plus $226 from 9 others

What the payments were for

  • Food & beverage$1,988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,988 in reported general payments places this provider in the 75th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$75,090
Medicare patients
333
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$30,646
LumiganBimatoprost66$28,087
XiidraLifitegrast18$26,272
TyrvayaVarenicline Tartrate32$20,209
Prednisolone Acetate198$5,721
CombiganBrimonidine Tartrate/Timolol12$5,618
VyzultaLatanoprostene Bunod12$5,553
Restasis MultidoseCyclosporine11$5,278
RhopressaNetarsudil Mesylate13$4,086
Ketorolac Tromethamine115$2,227
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,147
Travoprost12$2,040
Latanoprost167$1,612
Ofloxacin138$1,371
Brimonidine Tartrate148$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose$331$69,629128 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$481$31,82530 claims
Oyster Point Pharma, Inc.Tyrvaya$30$20,20932 claims
Aerie Pharmaceuticals, Inc.Rhopressa$71$4,08613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →